NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









ImmunoVec

ImmunoVec

Private
Los Angeles, CaliforniaHealthcare & Life Scienceshttps://immunovec.com/

Last Round

Seed Round

Jul 14, 2026

Total Funding Raised

$56.55M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

ImmunoVec is a biotechnology company developing a platform for in-vivo cell engineering to create therapies for autoimmune diseases, solid tumors, and genetic disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Advanced Materials, Clinical Trials

Business Model

B2G

Customer Profile

Government Contracts, Revenue Share, Services & Consulting

AI Layer

Non-AI

Keywords

in vivo cell engineeringnon-viral deliverygene therapyin vivo CAR-NKoff-the-shelf cell therapyCAR-NK therapydrug delivery platformpolymeric nanoparticlesgene deliveryautoimmune disease therapynon-LNP deliverypreclinical biotechsolid tumor therapyARPA-H

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ImmunoVec Comparables

Compare ImmunoVec with similar companies based on industry and business-model similarity.

ImmunoVec comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Alaya.bio
84%
AbbVie
84%
Aera Therapeutics
79%

ImmunoVec Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Seed RoundJul 14, 2026
Series AOct 8, 2025
GrantOct 8, 2025
GrantMay 29, 2025
SeedMar 2, 2022
Grant
Dec 2, 2021

Key People

Founding team and executive leadership

Ryan Wong

Chief Executive Officer

Executive Team

Feiyang Ma

Chief Technology Officer

Executive Team

ImmunoVec Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 8, 2025

    $41M grant awarded by ARPA-H

  • Oct 8, 2025

    Raised Series A with Anthem Venture Partners

ImmunoVec Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

ImmunoVec Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about ImmunoVec's valuation, stock price, and market status.

Firmographic Details

HeadquartersLos Angeles, California
Employee Range13
Year Founded2020
Last FundingJul 14, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.